Do analysts recommend GKOS or PHG?

Glaukos currently has a consensus price target of $149.17, indicating a potential upside of 13.98%. Given Glaukos' stronger consensus rating and higher probable upside, equities analysts plainly believe Glaukos is more favorable than Koninklijke Philips. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Glaukos 1 Sell rating(s) 1 Hold rating(s) 12 Buy rating(s) 0 Strong Buy rating(s) 2.79 Koninklijke Philips 0 Sell rating(s) 4 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has higher valuation & earnings, GKOS or PHG?

Koninklijke Philips has higher revenue and earnings than Glaukos. Glaukos is trading at a lower price-to-earnings ratio than Koninklijke Philips, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Glaukos $507.44M 15.15 -$187.69M -$3.28 N/A Koninklijke Philips $20.17B 1.28 $1.01B $1.17 22.89

Does the media favor GKOS or PHG?

In the previous week, Glaukos had 6 more articles in the media than Koninklijke Philips. MarketBeat recorded 7 mentions for Glaukos and 1 mentions for Koninklijke Philips. Glaukos' average media sentiment score of 1.03 beat Koninklijke Philips' score of 0.00 indicating that Glaukos is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Glaukos 6 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Koninklijke Philips 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher valuation & earnings, GKOS or ZBH?

Zimmer Biomet has higher revenue and earnings than Glaukos. Glaukos is trading at a lower price-to-earnings ratio than Zimmer Biomet, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Glaukos $507.44M 15.15 -$187.69M -$3.28 N/A Zimmer Biomet $8.23B 2.07 $705.20M $3.85 22.89

Is GKOS or ZBH more profitable?

Zimmer Biomet has a net margin of 9.05% compared to Glaukos' net margin of -34.34%. Zimmer Biomet's return on equity of 13.24% beat Glaukos' return on equity. Company Net Margins Return on Equity Return on Assets Glaukos -34.34% -6.92% -5.25% Zimmer Biomet 9.05% 13.24% 7.28%

Does the media prefer GKOS or ZBH?

In the previous week, Zimmer Biomet had 5 more articles in the media than Glaukos. MarketBeat recorded 12 mentions for Zimmer Biomet and 7 mentions for Glaukos. Zimmer Biomet's average media sentiment score of 1.06 beat Glaukos' score of 1.03 indicating that Zimmer Biomet is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Glaukos 6 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Zimmer Biomet 8 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation and earnings, SOLV or GKOS?

Solventum has higher revenue and earnings than Glaukos. Glaukos is trading at a lower price-to-earnings ratio than Solventum, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Solventum $8.33B 1.58 $1.56B $8.16 9.28 Glaukos $507.44M 15.15 -$187.69M -$3.28 N/A

Is SOLV or GKOS more profitable?

Solventum has a net margin of 17.33% compared to Glaukos' net margin of -34.34%. Solventum's return on equity of 23.51% beat Glaukos' return on equity. Company Net Margins Return on Equity Return on Assets Solventum 17.33% 23.51% 7.63% Glaukos -34.34% -6.92% -5.25%

Does the media favor SOLV or GKOS?

In the previous week, Glaukos had 6 more articles in the media than Solventum. MarketBeat recorded 7 mentions for Glaukos and 1 mentions for Solventum. Glaukos' average media sentiment score of 1.03 beat Solventum's score of 0.00 indicating that Glaukos is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Solventum 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Glaukos 6 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better earnings & valuation, SNN or GKOS?

Smith & Nephew SNATS has higher revenue and earnings than Glaukos. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Smith & Nephew SNATS $6.16B 2.08 $625M N/A N/A Glaukos $507.44M 15.15 -$187.69M -$3.28 N/A

Does the media refer more to SNN or GKOS?

In the previous week, Glaukos had 6 more articles in the media than Smith & Nephew SNATS. MarketBeat recorded 7 mentions for Glaukos and 1 mentions for Smith & Nephew SNATS. Glaukos' average media sentiment score of 1.03 beat Smith & Nephew SNATS's score of 0.33 indicating that Glaukos is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Smith & Nephew SNATS 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Glaukos 6 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable earnings and valuation, GKOS or PEN?

Penumbra has higher revenue and earnings than Glaukos. Glaukos is trading at a lower price-to-earnings ratio than Penumbra, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Glaukos $507.44M 15.15 -$187.69M -$3.28 N/A Penumbra $1.40B 8.88 $177.69M $4.34 73.01

Is GKOS or PEN more profitable?

Penumbra has a net margin of 11.76% compared to Glaukos' net margin of -34.34%. Penumbra's return on equity of 10.87% beat Glaukos' return on equity. Company Net Margins Return on Equity Return on Assets Glaukos -34.34% -6.92% -5.25% Penumbra 11.76% 10.87% 8.45%

Does the media refer more to GKOS or PEN?

In the previous week, Glaukos had 2 more articles in the media than Penumbra. MarketBeat recorded 7 mentions for Glaukos and 5 mentions for Penumbra. Glaukos' average media sentiment score of 1.03 beat Penumbra's score of 0.33 indicating that Glaukos is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Glaukos 6 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Penumbra 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Glaukos (GKOS) Competitors

$130.88 +3.47 (+2.72%)

Closing price 03:59 PM Eastern

Extended Trading

$130.66 -0.21 (-0.16%)

As of 04:24 PM Eastern

Compare

GKOS vs. PHG, ZBH, SOLV, SNN, and PEN

Should you buy Glaukos stock or one of its competitors? MarketBeat compares Glaukos with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Glaukos include Koninklijke Philips (PHG), Zimmer Biomet (ZBH), Solventum (SOLV), Smith & Nephew SNATS (SNN), and Penumbra (PEN). These companies are all part of the "medical equipment" industry.

How does Glaukos compare to Koninklijke Philips?

Glaukos (NYSE:GKOS) and Koninklijke Philips (NYSE:PHG) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, risk, dividends, analyst recommendations, institutional ownership, media sentiment, profitability and earnings.

Glaukos currently has a consensus price target of $149.17, indicating a potential upside of 13.98%. Given Glaukos' stronger consensus rating and higher probable upside, equities analysts plainly believe Glaukos is more favorable than Koninklijke Philips.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Glaukos	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.79
Koninklijke Philips	0 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Glaukos has a beta of 0.82, suggesting that its share price is 18% less volatile than the broader market. Comparatively, Koninklijke Philips has a beta of 0.74, suggesting that its share price is 26% less volatile than the broader market.

Koninklijke Philips has a net margin of 5.49% compared to Glaukos' net margin of -34.34%. Koninklijke Philips' return on equity of 13.51% beat Glaukos' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Glaukos	-34.34%	-6.92%	-5.25%
Koninklijke Philips	5.49%	13.51%	5.48%

99.0% of Glaukos shares are held by institutional investors. Comparatively, 13.7% of Koninklijke Philips shares are held by institutional investors. 5.9% of Glaukos shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Koninklijke Philips has higher revenue and earnings than Glaukos. Glaukos is trading at a lower price-to-earnings ratio than Koninklijke Philips, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Glaukos	$507.44M	15.15	-$187.69M	-$3.28	N/A
Koninklijke Philips	$20.17B	1.28	$1.01B	$1.17	22.89

In the previous week, Glaukos had 6 more articles in the media than Koninklijke Philips. MarketBeat recorded 7 mentions for Glaukos and 1 mentions for Koninklijke Philips. Glaukos' average media sentiment score of 1.03 beat Koninklijke Philips' score of 0.00 indicating that Glaukos is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Glaukos	6 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Koninklijke Philips	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Glaukos beats Koninklijke Philips on 9 of the 15 factors compared between the two stocks.

How does Glaukos compare to Zimmer Biomet?

Glaukos (NYSE:GKOS) and Zimmer Biomet (NYSE:ZBH) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, analyst recommendations, earnings, risk, profitability, media sentiment, valuation and institutional ownership.

Glaukos presently has a consensus target price of $149.17, suggesting a potential upside of 13.98%. Zimmer Biomet has a consensus target price of $102.70, suggesting a potential upside of 16.54%. Given Zimmer Biomet's higher probable upside, analysts clearly believe Zimmer Biomet is more favorable than Glaukos.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Glaukos	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.79
Zimmer Biomet	3 Sell rating(s)	12 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.26

Zimmer Biomet has higher revenue and earnings than Glaukos. Glaukos is trading at a lower price-to-earnings ratio than Zimmer Biomet, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Glaukos	$507.44M	15.15	-$187.69M	-$3.28	N/A
Zimmer Biomet	$8.23B	2.07	$705.20M	$3.85	22.89

Zimmer Biomet has a net margin of 9.05% compared to Glaukos' net margin of -34.34%. Zimmer Biomet's return on equity of 13.24% beat Glaukos' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Glaukos	-34.34%	-6.92%	-5.25%
Zimmer Biomet	9.05%	13.24%	7.28%

99.0% of Glaukos shares are owned by institutional investors. Comparatively, 88.9% of Zimmer Biomet shares are owned by institutional investors. 5.9% of Glaukos shares are owned by insiders. Comparatively, 1.3% of Zimmer Biomet shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

In the previous week, Zimmer Biomet had 5 more articles in the media than Glaukos. MarketBeat recorded 12 mentions for Zimmer Biomet and 7 mentions for Glaukos. Zimmer Biomet's average media sentiment score of 1.06 beat Glaukos' score of 1.03 indicating that Zimmer Biomet is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Glaukos	6 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Zimmer Biomet	8 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Glaukos has a beta of 0.82, suggesting that its stock price is 18% less volatile than the broader market. Comparatively, Zimmer Biomet has a beta of 0.47, suggesting that its stock price is 53% less volatile than the broader market.

Summary

Zimmer Biomet beats Glaukos on 10 of the 16 factors compared between the two stocks.

How does Glaukos compare to Solventum?

Solventum (NYSE:SOLV) and Glaukos (NYSE:GKOS) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, earnings, dividends, analyst recommendations, valuation and media sentiment.

Solventum has higher revenue and earnings than Glaukos. Glaukos is trading at a lower price-to-earnings ratio than Solventum, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Solventum	$8.33B	1.58	$1.56B	$8.16	9.28
Glaukos	$507.44M	15.15	-$187.69M	-$3.28	N/A

In the previous week, Glaukos had 6 more articles in the media than Solventum. MarketBeat recorded 7 mentions for Glaukos and 1 mentions for Solventum. Glaukos' average media sentiment score of 1.03 beat Solventum's score of 0.00 indicating that Glaukos is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Solventum	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Glaukos	6 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Solventum has a beta of 0.69, meaning that its stock price is 31% less volatile than the broader market. Comparatively, Glaukos has a beta of 0.82, meaning that its stock price is 18% less volatile than the broader market.

99.0% of Glaukos shares are held by institutional investors. 0.2% of Solventum shares are held by company insiders. Comparatively, 5.9% of Glaukos shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Solventum has a net margin of 17.33% compared to Glaukos' net margin of -34.34%. Solventum's return on equity of 23.51% beat Glaukos' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Solventum	17.33%	23.51%	7.63%
Glaukos	-34.34%	-6.92%	-5.25%

Solventum presently has a consensus target price of $84.25, indicating a potential upside of 11.26%. Glaukos has a consensus target price of $149.17, indicating a potential upside of 13.98%. Given Glaukos' stronger consensus rating and higher possible upside, analysts clearly believe Glaukos is more favorable than Solventum.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Solventum	1 Sell rating(s)	5 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.50
Glaukos	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.79

Summary

Glaukos beats Solventum on 9 of the 15 factors compared between the two stocks.

How does Glaukos compare to Smith & Nephew SNATS?

Smith & Nephew SNATS (NYSE:SNN) and Glaukos (NYSE:GKOS) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, dividends, media sentiment, risk, valuation, profitability and analyst recommendations.

25.6% of Smith & Nephew SNATS shares are owned by institutional investors. Comparatively, 99.0% of Glaukos shares are owned by institutional investors. 1.0% of Smith & Nephew SNATS shares are owned by company insiders. Comparatively, 5.9% of Glaukos shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, Glaukos had 6 more articles in the media than Smith & Nephew SNATS. MarketBeat recorded 7 mentions for Glaukos and 1 mentions for Smith & Nephew SNATS. Glaukos' average media sentiment score of 1.03 beat Smith & Nephew SNATS's score of 0.33 indicating that Glaukos is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Smith & Nephew SNATS	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Glaukos	6 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Smith & Nephew SNATS currently has a consensus target price of $30.93, indicating a potential upside of 2.72%. Glaukos has a consensus target price of $149.17, indicating a potential upside of 13.98%. Given Glaukos' stronger consensus rating and higher probable upside, analysts clearly believe Glaukos is more favorable than Smith & Nephew SNATS.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Smith & Nephew SNATS	0 Sell rating(s)	5 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.17
Glaukos	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.79

Smith & Nephew SNATS has a beta of 0.55, suggesting that its share price is 45% less volatile than the broader market. Comparatively, Glaukos has a beta of 0.82, suggesting that its share price is 18% less volatile than the broader market.

Smith & Nephew SNATS has higher revenue and earnings than Glaukos.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Smith & Nephew SNATS	$6.16B	2.08	$625M	N/A	N/A
Glaukos	$507.44M	15.15	-$187.69M	-$3.28	N/A

Smith & Nephew SNATS has a net margin of 0.00% compared to Glaukos' net margin of -34.34%. Smith & Nephew SNATS's return on equity of 0.00% beat Glaukos' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Smith & Nephew SNATS	N/A	N/A	N/A
Glaukos	-34.34%	-6.92%	-5.25%

Summary

Glaukos beats Smith & Nephew SNATS on 9 of the 14 factors compared between the two stocks.

How does Glaukos compare to Penumbra?

Glaukos (NYSE:GKOS) and Penumbra (NYSE:PEN) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, media sentiment, profitability, dividends, analyst recommendations and valuation.

In the previous week, Glaukos had 2 more articles in the media than Penumbra. MarketBeat recorded 7 mentions for Glaukos and 5 mentions for Penumbra. Glaukos' average media sentiment score of 1.03 beat Penumbra's score of 0.33 indicating that Glaukos is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Glaukos	6 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Penumbra	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Glaukos currently has a consensus target price of $149.17, suggesting a potential upside of 13.98%. Penumbra has a consensus target price of $361.33, suggesting a potential upside of 14.03%. Given Penumbra's higher probable upside, analysts clearly believe Penumbra is more favorable than Glaukos.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Glaukos	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.79
Penumbra	0 Sell rating(s)	14 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.18

Penumbra has a net margin of 11.76% compared to Glaukos' net margin of -34.34%. Penumbra's return on equity of 10.87% beat Glaukos' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Glaukos	-34.34%	-6.92%	-5.25%
Penumbra	11.76%	10.87%	8.45%

Glaukos has a beta of 0.82, meaning that its stock price is 18% less volatile than the broader market. Comparatively, Penumbra has a beta of 0.71, meaning that its stock price is 29% less volatile than the broader market.

Penumbra has higher revenue and earnings than Glaukos. Glaukos is trading at a lower price-to-earnings ratio than Penumbra, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Glaukos	$507.44M	15.15	-$187.69M	-$3.28	N/A
Penumbra	$1.40B	8.88	$177.69M	$4.34	73.01

99.0% of Glaukos shares are owned by institutional investors. Comparatively, 88.9% of Penumbra shares are owned by institutional investors. 5.9% of Glaukos shares are owned by insiders. Comparatively, 2.9% of Penumbra shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Glaukos beats Penumbra on 8 of the 15 factors compared between the two stocks.

Get Glaukos News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GKOS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

GKOS vs. The Competition

Export

Metric	Glaukos	MED INSTRUMENTS Industry	Medical Sector	NYSE Exchange
Market Cap	$7.48B	$6.97B	$6.40B	$23.18B
Dividend Yield	N/A	1.21%	2.67%	4.07%
P/E Ratio	N/A	47.59	24.51	31.62
Price / Sales	15.15	86.67	553.78	103.59
Price / Cash	N/A	25.19	43.94	24.31
Price / Book	11.46	7.16	10.70	4.68
Net Income	-$187.69M	$159.20M	$3.57B	$1.08B
7 Day Performance	5.31%	-1.24%	0.56%	-0.26%
1 Month Performance	-8.11%	4.53%	3.57%	2.18%
1 Year Performance	27.92%	5.36%	28.49%	24.66%

Glaukos Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
GKOS Glaukos	3.6384 of 5 stars	$130.88 +2.7%	$149.17 +14.0%	+27.3%	$7.48B	$507.44M	N/A	1,094	Positive News Analyst Forecast
PHG Koninklijke Philips	2.1506 of 5 stars	$25.83 -1.1%	N/A	+18.6%	$25.14B	$20.17B	22.13	65,340	Analyst Downgrade
ZBH Zimmer Biomet	4.6892 of 5 stars	$87.34 +0.0%	$102.70 +17.6%	-3.4%	$16.90B	$8.23B	22.69	17,000	Positive News
SOLV Solventum	2.8538 of 5 stars	$78.70 -2.8%	$84.25 +7.0%	+2.3%	$14.03B	$8.33B	9.64	20,000
SNN Smith & Nephew SNATS	1.9131 of 5 stars	$30.37 -0.8%	$30.93 +1.8%	+5.2%	$13.07B	$6.16B	N/A	16,988

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:GKOS) was last updated on 6/18/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Glaukos (GKOS) Competitors

GKOS vs. PHG, ZBH, SOLV, SNN, and PEN

How does Glaukos compare to Koninklijke Philips?

Summary

How does Glaukos compare to Zimmer Biomet?

Summary

How does Glaukos compare to Solventum?

Summary

How does Glaukos compare to Smith & Nephew SNATS?

Summary

How does Glaukos compare to Penumbra?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GKOS vs. The Competition

Glaukos Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Glaukos (GKOS) Competitors

GKOS vs. PHG, ZBH, SOLV, SNN, and PEN

How does Glaukos compare to Koninklijke Philips?

Do analysts recommend GKOS or PHG?

Which has more risk & volatility, GKOS or PHG?

Is GKOS or PHG more profitable?

Do institutionals and insiders hold more shares of GKOS or PHG?

Which has higher valuation & earnings, GKOS or PHG?

Does the media favor GKOS or PHG?

Summary

How does Glaukos compare to Zimmer Biomet?

Do analysts rate GKOS or ZBH?

Which has higher valuation & earnings, GKOS or ZBH?

Is GKOS or ZBH more profitable?

Do institutionals & insiders hold more shares of GKOS or ZBH?

Does the media prefer GKOS or ZBH?

Which has more volatility and risk, GKOS or ZBH?

Summary

How does Glaukos compare to Solventum?

Which has higher valuation and earnings, SOLV or GKOS?

Does the media favor SOLV or GKOS?

Which has more risk & volatility, SOLV or GKOS?

Do insiders & institutionals believe in SOLV or GKOS?

Is SOLV or GKOS more profitable?

Do analysts recommend SOLV or GKOS?

Summary

How does Glaukos compare to Smith & Nephew SNATS?

Do institutionals & insiders have more ownership in SNN or GKOS?

Does the media refer more to SNN or GKOS?

Do analysts rate SNN or GKOS?

Which has more risk & volatility, SNN or GKOS?

Which has better earnings & valuation, SNN or GKOS?

Is SNN or GKOS more profitable?

Summary

How does Glaukos compare to Penumbra?

Does the media refer more to GKOS or PEN?

Do analysts rate GKOS or PEN?

Is GKOS or PEN more profitable?

Which has more volatility and risk, GKOS or PEN?

Which has preferable earnings and valuation, GKOS or PEN?

Do insiders and institutionals have more ownership in GKOS or PEN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GKOS vs. The Competition

Glaukos Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools